Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Estetrol/Drospirenone

Phase 3Small molecule

AAndrew Zakhari

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

EndometriomaRecruiting

EndometriomaPhase 3

Recruiting

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Endometrioma

NCT05837624

Clinical

Trials by Indication[1]

Endometrioma1 trial

Estetrol/Drospirenone to Reduce the Average Size of Endometriomas

Recruiting·AAndrew Zakhari·Phase 4·NCT05837624·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Estetrol/Drospirenone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Estetrol/Drospirenone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Estetrol/Drospirenone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Andrew Zakhari company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAndrew Zakhari

Related News